KRAS and non-small cell lung carcinoma: Concurrent and mutual exclusion analysis indicated that EML4-ALK fusion was mutually exclusive with EGFR mutations (Supplementary Fig. 12), consistent with a recent large-scale clinical screening of NSCLC for EGFR, KRAS mutations and ALK rearrangements38.